SE469059B - Anvaendning av acyloxialkanoylkolinsalt foer framstaellning av laekemedel foer behandling av neuropsykiatriska symtom som aatfoeljer demens - Google Patents
Anvaendning av acyloxialkanoylkolinsalt foer framstaellning av laekemedel foer behandling av neuropsykiatriska symtom som aatfoeljer demensInfo
- Publication number
- SE469059B SE469059B SE8604950A SE8604950A SE469059B SE 469059 B SE469059 B SE 469059B SE 8604950 A SE8604950 A SE 8604950A SE 8604950 A SE8604950 A SE 8604950A SE 469059 B SE469059 B SE 469059B
- Authority
- SE
- Sweden
- Prior art keywords
- acyloxyalkanoylcholine
- salt according
- dementia
- salt
- neuropsychiatric symptoms
- Prior art date
Links
- 208000024891 symptom Diseases 0.000 title claims description 11
- 229940126601 medicinal product Drugs 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 title description 6
- 239000004381 Choline salt Substances 0.000 title 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical class C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 title 1
- 235000019417 choline salt Nutrition 0.000 title 1
- 239000003814 drug Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 206010012289 Dementia Diseases 0.000 claims description 14
- SRZGFCNCQUMTCP-UHFFFAOYSA-N aclatonium Chemical compound CC(=O)OC(C)C(=O)OCC[N+](C)(C)C SRZGFCNCQUMTCP-UHFFFAOYSA-N 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 206010039966 Senile dementia Diseases 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- -1 sulfonyloxy groups Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-L naphthalene-1,5-disulfonate(2-) Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1S([O-])(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-L 0.000 claims description 2
- PNMBDZXCNXEXEC-UHFFFAOYSA-M 2-(2-acetyloxypropanoyloxy)ethyl-trimethylazanium;4-methylbenzenesulfonate Chemical group CC1=CC=C(S([O-])(=O)=O)C=C1.CC(=O)OC(C)C(=O)OCC[N+](C)(C)C PNMBDZXCNXEXEC-UHFFFAOYSA-M 0.000 claims 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 19
- 229950008605 aclatonium Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 230000002490 cerebral effect Effects 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 6
- 238000002591 computed tomography Methods 0.000 description 6
- 208000000044 Amnesia Diseases 0.000 description 4
- 206010008096 Cerebral atrophy Diseases 0.000 description 4
- 208000026139 Memory disease Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000006984 memory degeneration Effects 0.000 description 4
- 208000023060 memory loss Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 210000004289 cerebral ventricle Anatomy 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101100020289 Xenopus laevis koza gene Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- PSRFOBQQWDICLU-UHFFFAOYSA-N benzene-1,2,4-trisulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(S(O)(=O)=O)C(S(O)(=O)=O)=C1 PSRFOBQQWDICLU-UHFFFAOYSA-N 0.000 description 1
- RBUBFLVZIXNHTE-UHFFFAOYSA-N benzene-1,3,5-trisulfonic acid Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1 RBUBFLVZIXNHTE-UHFFFAOYSA-N 0.000 description 1
- WRUAHXANJKHFIL-UHFFFAOYSA-N benzene-1,3-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC(S(O)(=O)=O)=C1 WRUAHXANJKHFIL-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000020089 femoral neck fracture Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000002362 mulch Substances 0.000 description 1
- 229950005216 napadisilate Drugs 0.000 description 1
- SITVNOOPPBSYNB-UHFFFAOYSA-N naphthalene-1,3,5,7-tetrasulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=CC(S(=O)(=O)O)=CC(S(O)(=O)=O)=C21 SITVNOOPPBSYNB-UHFFFAOYSA-N 0.000 description 1
- INMHJULHWVWVFN-UHFFFAOYSA-N naphthalene-1,3,5-trisulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(S(=O)(=O)O)=CC(S(O)(=O)=O)=C21 INMHJULHWVWVFN-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- FITZJYAVATZPMJ-UHFFFAOYSA-N naphthalene-2,6-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=CC2=CC(S(=O)(=O)O)=CC=C21 FITZJYAVATZPMJ-UHFFFAOYSA-N 0.000 description 1
- VILFVXYKHXVYAB-UHFFFAOYSA-N naphthalene-2,7-disulfonic acid Chemical compound C1=CC(S(O)(=O)=O)=CC2=CC(S(=O)(=O)O)=CC=C21 VILFVXYKHXVYAB-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60257881A JPH0733332B2 (ja) | 1985-11-19 | 1985-11-19 | 痴呆症状改善・治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8604950D0 SE8604950D0 (sv) | 1986-11-19 |
| SE8604950L SE8604950L (sv) | 1987-05-20 |
| SE469059B true SE469059B (sv) | 1993-05-10 |
Family
ID=17312478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8604950A SE469059B (sv) | 1985-11-19 | 1986-11-19 | Anvaendning av acyloxialkanoylkolinsalt foer framstaellning av laekemedel foer behandling av neuropsykiatriska symtom som aatfoeljer demens |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4713376A (enExample) |
| JP (1) | JPH0733332B2 (enExample) |
| AU (1) | AU590640B2 (enExample) |
| CA (1) | CA1278519C (enExample) |
| CH (1) | CH668184A5 (enExample) |
| DE (1) | DE3639378A1 (enExample) |
| DK (1) | DK169607B1 (enExample) |
| FR (1) | FR2590170B1 (enExample) |
| GB (1) | GB2184653B (enExample) |
| IT (1) | IT1200041B (enExample) |
| NL (1) | NL8602933A (enExample) |
| SE (1) | SE469059B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040208875A1 (en) * | 1995-03-15 | 2004-10-21 | Queen's University At Kingston | Method for treating amyloidosis |
| US20020022657A1 (en) * | 1998-02-11 | 2002-02-21 | Francine Gervais | Methods for modulating neuronal cell death |
| US6322824B1 (en) * | 1998-02-13 | 2001-11-27 | Willmar Schwabe Gmbh & Co. | Use of hyperforin and hyperforin-containing extracts in the treatment of dementia diseases |
| US7414076B2 (en) * | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20070010573A1 (en) * | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| EP1660434A1 (en) * | 2003-08-15 | 2006-05-31 | PATEL, Hasmukh B. | Choline esters useful for the treatment of cognitive dysfunctions and enhancement of memory, learning and cognition |
| US7803842B2 (en) * | 2004-06-08 | 2010-09-28 | Hass Patel | Choline esters useful for the treatment of cognitive dysfunctions and enhancement of memory, learning and cognition |
| BRPI0517790A (pt) * | 2004-11-12 | 2008-10-21 | Neurochem Int Ltd | métodos e composições fluoradas para tratar doenças relacionadas à amilóide |
| CA2586334A1 (en) * | 2004-11-16 | 2006-06-08 | Neurochem (International) Limited | Compounds for the treatment of cns and amyloid associated diseases |
| WO2006085149A2 (en) | 2004-12-22 | 2006-08-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
| MX2008008213A (es) * | 2005-12-22 | 2008-09-03 | Neurochem Int Ltd | Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias. |
| KR101608445B1 (ko) | 2006-10-12 | 2016-04-01 | 비에이치아이 리미티드 파트너쉽 | 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클 |
| EP2120905A1 (en) * | 2006-12-22 | 2009-11-25 | BELLUS Health (International) Limited | Methods, compounds, and compositions for treating metabolic disorders and diabetes |
| BRPI0807004A2 (pt) * | 2007-02-07 | 2014-04-15 | Argenta Discovery Ltd | Sal |
| TW201115409A (en) * | 2009-10-29 | 2011-05-01 | Hannspree Inc | A mouse capable of generating vapor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1336350A (en) * | 1970-12-28 | 1973-11-07 | Toyama Chemical Co Ltd | Choline derivatives and process for producing the same |
| DE2425983C3 (de) * | 1973-06-12 | 1978-09-14 | Toyama Chemical Co. Ltd., Tokio | Sulfonsäuresalze von Acylcholinen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| JPS5221490A (en) * | 1975-08-12 | 1977-02-18 | Mitsubishi Rayon Co | Printing method |
| JPS592904B2 (ja) * | 1976-09-18 | 1984-01-21 | 日本ビクター株式会社 | デイスプレイ装置 |
| JPS551251A (en) * | 1978-06-20 | 1980-01-08 | Yamaha Motor Co Ltd | Brake pedal for motorcycle |
| JPS58180463A (ja) * | 1982-04-19 | 1983-10-21 | Toyama Chem Co Ltd | ビスコリンジスルホナ−ト類の製造法 |
-
1985
- 1985-11-19 JP JP60257881A patent/JPH0733332B2/ja not_active Expired - Lifetime
-
1986
- 1986-11-14 US US06/930,452 patent/US4713376A/en not_active Expired - Fee Related
- 1986-11-17 AU AU65302/86A patent/AU590640B2/en not_active Ceased
- 1986-11-18 DE DE19863639378 patent/DE3639378A1/de active Granted
- 1986-11-18 CH CH4605/86A patent/CH668184A5/de not_active IP Right Cessation
- 1986-11-18 CA CA000523280A patent/CA1278519C/en not_active Expired - Lifetime
- 1986-11-18 GB GB8627484A patent/GB2184653B/en not_active Expired
- 1986-11-18 DK DK550586A patent/DK169607B1/da not_active IP Right Cessation
- 1986-11-19 SE SE8604950A patent/SE469059B/sv not_active IP Right Cessation
- 1986-11-19 NL NL8602933A patent/NL8602933A/nl active Search and Examination
- 1986-11-19 FR FR868616107A patent/FR2590170B1/fr not_active Expired - Lifetime
- 1986-11-19 IT IT48670/86A patent/IT1200041B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62120317A (ja) | 1987-06-01 |
| DK550586A (da) | 1987-05-20 |
| NL8602933A (nl) | 1987-06-16 |
| SE8604950L (sv) | 1987-05-20 |
| JPH0733332B2 (ja) | 1995-04-12 |
| CA1278519C (en) | 1991-01-02 |
| GB8627484D0 (en) | 1986-12-17 |
| DE3639378A1 (de) | 1987-05-27 |
| US4713376A (en) | 1987-12-15 |
| DE3639378C2 (enExample) | 1990-05-10 |
| SE8604950D0 (sv) | 1986-11-19 |
| FR2590170A1 (fr) | 1987-05-22 |
| GB2184653B (en) | 1989-11-15 |
| AU590640B2 (en) | 1989-11-09 |
| DK169607B1 (da) | 1994-12-27 |
| DK550586D0 (da) | 1986-11-18 |
| IT1200041B (it) | 1989-01-05 |
| FR2590170B1 (fr) | 1990-08-24 |
| AU6530286A (en) | 1987-05-21 |
| GB2184653A (en) | 1987-07-01 |
| IT8648670A0 (it) | 1986-11-19 |
| CH668184A5 (de) | 1988-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69201948T2 (de) | Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b. | |
| EP0760664B1 (de) | Verwendung von pteridin-derivaten als hemmstoffe der no-synthase | |
| US4713376A (en) | Dementia-improving and therapeutic agents | |
| US20080207649A1 (en) | Method of treating brain ischemia | |
| SE448517B (sv) | Farmaceutiskt preparat som paverkar det centrala nervsystemet, innehallande 1,3-dimetyl-5-aminoadamantan och en metylxantinforening | |
| DE4442116A1 (de) | 2-Amino-1,3-thiazine als Hemmstoffe der Stickstoffmonoxid-Synthase | |
| SE450251B (sv) | Xantatforeningar for terapeutisk anvendning, nya xantatforeningar samt terapeutiska kompositioner innehallande dessa foreningar | |
| US6399658B1 (en) | Composition containing ascorbic acid | |
| MC1575A1 (fr) | Nouveau derives de la guanine | |
| DE69426620T2 (de) | Antidepressiva | |
| JPS58174313A (ja) | 動物組織の線維化抑制剤 | |
| EP1084704B1 (en) | Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia | |
| HU190597B (en) | Process for preparing synrtgetic pharmaceutical compositions | |
| EP0137514B1 (en) | Compounds and compositions for use in preventing and treating obesity | |
| NZ204072A (en) | Pharmaceutical compositions which contain theophylline as active ingredient | |
| US4469707A (en) | Method for treatment of senile dementia | |
| DE60026559T2 (de) | Arzneimittel gegen essstörungen | |
| US3891769A (en) | Psychotherapeutic methods employing thioureas | |
| IE43338B1 (en) | Pharmaceutical compositions | |
| WO1991001136A1 (de) | Tetrahydrobenzthiazolderivate zur behandlung von augenkrankheiten | |
| JPH03232870A (ja) | チオアミド化合物 | |
| US3426129A (en) | Treatment of depression of the central nervous system with alkyl esters of 1-aziridinepropionic acid | |
| HU188015B (en) | Process for the preparation of antidiabetes compositions | |
| JPS58174321A (ja) | 抗糖尿病組成物 | |
| JPWO1998027982A1 (ja) | アスコルビン酸含有組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8604950-9 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8604950-9 Format of ref document f/p: F |